Last reviewed · How we verify
ALD403
ALD403 is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.
ALD403 is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis. Used for Migraine prevention (episodic and chronic).
At a glance
| Generic name | ALD403 |
|---|---|
| Also known as | Eptinezumab-jjmr, Vyepti |
| Sponsor | Alder Biopharmaceuticals, Inc. |
| Drug class | CGRP monoclonal antibody |
| Target | CGRP (Calcitonin Gene-Related Peptide) |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
CGRP is released during migraine attacks and contributes to vasodilation, neurogenic inflammation, and pain signal transmission. By binding to and neutralizing CGRP, ALD403 prevents its interaction with CGRP receptors on neurons and blood vessels, thereby reducing migraine frequency and severity. This mechanism has demonstrated efficacy in preventing both episodic and chronic migraines.
Approved indications
- Migraine prevention (episodic and chronic)
Common side effects
- Injection site reactions
- Nasopharyngitis
- Upper respiratory tract infection
Key clinical trials
- Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients. (NA)
- Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (PHASE3)
- A Multicenter Assessment of ALD403 in Frequent Episodic Migraine (PHASE3)
- An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine (PHASE3)
- A Multicenter Assessment of ALD403 in Chronic Migraine (PHASE2)
- Safety, Efficacy and Pharmacokinetics of ALD403 (PHASE1)
- Safety Tolerability and Pharmacokinetics of ALD403 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |